Back to search results

IPH4502 for Advanced Solid Tumors

This study is testing a new drug called IPH4502 in people with advanced solid tumors (cancers that form solid masses) that have spread or cannot be removed by surgery. To join, your tumor must express Nectin-4 (a specific protein on cancer cells) and you must have tried other treatments without success. The main goal of this study is to see how safe IPH4502 is and what side effects it might cause. Researchers will also look at how well the drug works. The study is currently open and plans to enroll about 145 participants.

Study design
This is a Phase 1, open-label study, meaning both you and your doctors will know you are receiving IPH4502. It is a single-arm study, so all participants will receive the study drug. The study will enroll about 145 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for safety and tolerability from the time of your first dose through the treatment period, including follow-up, for up to 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06781983

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
Innate Pharma
~145 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:IPH4502

At a glance

Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Tolerability
Measured over From time of first dose through treatment period, including the follow-up: up to 24 months

Conditions

Advanced or Metastatic Solid Tumors

Explore related trials

Cervical CarcinomaColorectal CarcinomaEsophageal and Gastroesophageal Junction CarcinomaEsophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaLung Non-Small Cell CarcinomaMelanomaOvarian CarcinomaProstate CarcinomaSolid NeoplasmTriple-negative breast cancerUrothelial CarcinomaNectin-4

Where it's being run

7 sites across 6 states
France2
Massachusetts1
New Jersey1
New York1
Texas1
Virginia1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4
Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is available.
Measurable disease according to RECIST 1.1.
Archival tumor tissue obtained within 4 months of screening and since the last anticancer therapy prior to the study or agree to undergo a tumor biopsy at baseline.
Adequate organ function and hematological function.

Exclusion

Known or suspected brain metastases.
Participants with an active infection, Any other infection requiring systemic treatment or latent infection.
Participants with clinically significant comorbidity(s).
History of treatment for, or suspicion or confirmed interstitial lung disease (ILD) at baseline.
Condition being treated with systemic corticosteroids or immunosuppressive therapy during IPH4502 treatment.
Thromboembolic event requiring anticoagulation therapy ≤14 days prior to the first dose of IPH4502.
Clinically significant cardiovascular disease and/or cardiac repolarization abnormality.
Participants with symptomatic heart failure, Acute coronary syndromes
Participant is receiving or has received anticancer therapy prior to enrolment that may have impact on the assessment of IPH4502.
Major surgery ≤28 days and minor surgery ≤7 days prior to first dose of IPH4502 or 6 months for coronary artery bypass surgery.
Concomitant medications or vaccines : Live-attenuated vaccines ≤ 6 weeks prior to first dose of IPH4502; systemic corticosteroids or other immunosuppressive agents within 14 days prior to the first dose of IPH4502; systemic use of moderate or strong CYP 3A4 inhibitors; systemic use of moderate or strong CYP 3A4 inducers.

What this trial measures

  • Safety and TolerabilityFrom time of first dose through treatment period, including the follow-up: up to 24 months

    To evaluate the incidence of AEs, SAEs, TEAEs, and DLTs.